• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

18F-FES PET 在播散性小叶乳腺癌患者的分期和治疗决策中具有附加价值。

18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer.

机构信息

From the Departments of *Medical Oncology, and †Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

出版信息

Clin Nucl Med. 2017 Aug;42(8):612-614. doi: 10.1097/RLU.0000000000001724.

DOI:10.1097/RLU.0000000000001724
PMID:28604479
Abstract

Lobular breast cancer is the second most common type of invasive breast cancer. Lobular breast cancer lesions are often difficult to detect with conventional imaging because they tend to grow less cohesively than ductal cancer. These images represent 3 lobular breast cancer cases, in whom confirmation of metastatic disease would make the crucial difference between curative or noncurative treatment. Staging with conventional imaging, however, yielded equivocal results, and a biopsy was not feasible. In contrast, FES (16α-[F]fluoro-17β-estradiol) PET provided a decisive contribution to clinical decision making in these patients. This indicates that FES PET may have added value in relation to conventional staging.

摘要

乳腺小叶癌是第二常见的浸润性乳腺癌类型。乳腺小叶癌病变通常很难用常规成像检测到,因为它们的生长方式不如导管癌那样具有凝聚力。这些图像代表了 3 例乳腺小叶癌患者,在这些患者中,转移性疾病的确诊将对治愈性或非治愈性治疗产生至关重要的影响。然而,常规成像分期的结果模棱两可,且活检不可行。相比之下,FES(16α-[F]氟-17β-雌二醇)PET 为这些患者的临床决策提供了决定性的帮助。这表明 FES PET 在常规分期方面可能具有附加价值。

相似文献

1
18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer.18F-FES PET 在播散性小叶乳腺癌患者的分期和治疗决策中具有附加价值。
Clin Nucl Med. 2017 Aug;42(8):612-614. doi: 10.1097/RLU.0000000000001724.
2
Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.16α-18F-氟-17β-雌二醇正电子发射断层扫描全身特征在转移性乳腺癌中雌激素受体状态的评估:荟萃分析和纳入临床应用的建议。
Oncologist. 2020 Oct;25(10):835-844. doi: 10.1634/theoncologist.2019-0967. Epub 2020 May 15.
3
Diagnostic accuracy and safety of 16α-[F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.16α-[F]氟-17β-雌二醇 PET-CT 评估乳腺癌复发或转移病灶中雌激素受体状态的诊断准确性和安全性:一项前瞻性队列研究。
Lancet Oncol. 2019 Apr;20(4):546-555. doi: 10.1016/S1470-2045(18)30936-7. Epub 2019 Mar 4.
4
Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.18F-FDG PET/CT用于新诊断的浸润性小叶癌与浸润性导管癌全身分期的比较
J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.
5
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.2-[18F]氟-2-脱氧-D-葡萄糖和16α-[18F]氟-17β-雌二醇正电子发射断层扫描在乳腺癌中的应用:与雌激素受体状态及全身治疗反应的相关性
Clin Cancer Res. 1996 Jun;2(6):933-9.
6
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.16α-[18F]氟-17β-雌二醇 PET 用于活体雌激素受体成像的推荐意见和技术要点:格罗宁根经验。
Clin Nucl Med. 2016 Nov;41(11):844-851. doi: 10.1097/RLU.0000000000001347.
7
The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.16α-[18F]氟雌二醇PET/CT在辅助乳腺癌患者个体化治疗决策中的初步研究。
PLoS One. 2015 Jan 24;10(1):e0116341. doi: 10.1371/journal.pone.0116341. eCollection 2015.
8
Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[F]Fluoro-17β-Estradiol PET.摘要:使用 16α-[F]氟-17β-雌二醇 PET 进行乳腺癌患者雌激素受体成像的 SNMMI 程序标准/EANM 实践指南。
J Nucl Med. 2024 Feb 1;65(2):221-223. doi: 10.2967/jnumed.123.266938.
9
Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.使用雌二醇或睾酮的氟化类似物对性激素受体进行PET成像的当前应用。
Q J Nucl Med Mol Imaging. 2015 Mar;59(1):4-17. Epub 2015 Feb 19.
10
The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.使用FES或FDG示踪剂的PET/CT在转移性乳腺癌中的价值:一项针对雌激素受体阳性患者的计算机模拟研究
Br J Cancer. 2015 May 12;112(10):1617-25. doi: 10.1038/bjc.2015.138. Epub 2015 Apr 16.

引用本文的文献

1
Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report.男性隐匿性原发性乳腺癌伴小肠转移:一例报告
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.24-0089. Epub 2025 May 16.
2
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer.[18F]氟雌二醇正电子发射断层扫描(FES-PET)和[18F]氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)成像可能有助于转移性小叶乳腺癌患者的治疗管理。
Mol Imaging Biol. 2025 May 14. doi: 10.1007/s11307-025-02015-2.
3
Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
保乳手术后不同组织学亚型的切缘阳性率:一项评估肿瘤整形手术影响的系统评价和荟萃分析
Ann Surg Oncol. 2025 Apr 24. doi: 10.1245/s10434-025-17329-2.
4
Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications.探索放射性碘标记阿那曲唑和表柔比星作为乳腺癌 AKT1 靶向放射性药物:计算机模拟分析和具有功能核成像意义的潜在治疗效果。
Molecules. 2024 Sep 4;29(17):4203. doi: 10.3390/molecules29174203.
5
WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers.WNT4 通过在乳腺和妇科癌症中线粒体的细胞内活性调节细胞代谢。
Cancer Res Commun. 2024 Jan 17;4(1):134-151. doi: 10.1158/2767-9764.CRC-23-0275.
6
FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma.用于浸润性小叶癌PET成像的氟代脱氧葡萄糖及非氟代脱氧葡萄糖放射性药物
Biomedicines. 2023 May 3;11(5):1350. doi: 10.3390/biomedicines11051350.
7
Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma.[18F]氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描成像在浸润性小叶癌首次复发中的应用
J Clin Med. 2023 Apr 17;12(8):2916. doi: 10.3390/jcm12082916.
8
Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.用于雌激素受体阳性乳腺癌的分子成像:全身和专用乳腺正电子发射断层扫描的临床应用。
Surg Oncol Clin N Am. 2022 Oct;31(4):569-579. doi: 10.1016/j.soc.2022.06.001.
9
PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.PET-CT在临床成人肿瘤学中的应用:II. 原发性胸部和乳腺恶性肿瘤
Cancers (Basel). 2022 May 29;14(11):2689. doi: 10.3390/cancers14112689.
10
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?按组织学亚型划分的乳腺癌试验入组人数减少:浸润性小叶癌是否抗拒RECIST标准?
NPJ Breast Cancer. 2021 Oct 25;7(1):139. doi: 10.1038/s41523-021-00348-z.